Skip to main content
Skip to main content
VMD logo

Viemed Healthcare, Inc. (VMD)

$12.32 +$0.30 (+2.46%) |Exceptional · 91
Signals are mixed — the Council read leans STRONG BUY (77/100) while the AI fundamental score is 91/100 (grade A+); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Moon AI bullish.
MCap: $472.12M| P/E Ratio: 26.9| Vol: 212.3K| Target: $13.00 (+5.6%)| 52-wk range: $5.93 – $10.68
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Viemed Healthcare, Inc. (VMD) trades at $12.32 with AI Score 91/100 (Grade A+). Viemed Healthcare, Inc. provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services in the United States. Market cap: $472.12M, Sector: Healthcare.

Price live · AI analysis from May 9, 2026
Viemed Healthcare, Inc. provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services in the United States. The company focuses on respiratory disease management, including COPD treatment and sleep apnea solutions.

VMD stock analysis for 2026: Analysts have set a consensus price target of $13.00 for Viemed Healthcare, Inc., suggesting 5.6% upside from the current price of $12.32. The AI MoonshotScore is 91/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
STRONG BUY 77/100 · A

VMD: 5/7 perspectives are bullish. Dominant signal: Moon AI bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Neutral
Jim Simons
Bullish
Izzy Englander
Neutral
Seth Klarman
Bullish
Moon AI
Bullish
Council Score · 8 perspectives · See tabs for details →

Viemed Healthcare, Inc. (VMD) Healthcare & Pipeline Overview

CEOCasey Hoyt
Employees1222
HeadquartersLafayette, LA, US
IPO Year2019

Viemed Healthcare, Inc. specializes in providing in-home respiratory care solutions and durable medical equipment, primarily targeting patients with COPD and sleep apnea. With a focus on non-invasive ventilation and related services, Viemed distinguishes itself through its comprehensive respiratory disease management programs and direct-to-patient service model within the medical devices sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 9, 2026

What Is the Investment Thesis for VMD?

Viemed Healthcare presents a focused investment opportunity within the respiratory care segment of the medical devices industry. With a market capitalization of $472.12M and a profit margin of 5.2%, the company demonstrates a capacity for profitability. Key value drivers include the increasing prevalence of COPD and sleep apnea, which fuels demand for Viemed's respiratory solutions. Growth catalysts include expanding its geographic reach and service offerings, particularly in the sleep apnea market. However, investors may want to evaluate potential risks such as regulatory changes and reimbursement pressures within the healthcare sector. The company's free cash flow of $0.03 billion provides financial flexibility for strategic initiatives.

Based on FMP financials and quantitative analysis

VMD Key Highlights

  • Market Cap of $472.12M indicates a mid-sized player in the medical devices market.
  • Profit Margin of 5.2% demonstrates profitability, albeit with room for improvement compared to industry leaders.
  • Gross Margin of 57.5% reflects efficient cost management in the provision of DME and respiratory services.
  • Free Cash Flow of $0.03B provides financial flexibility for growth initiatives and potential acquisitions.
  • Beta of 1.16 suggests slightly higher volatility compared to the overall market.

Who Are VMD's Competitors?

VMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
DCTH Delcath Systems, Inc. $13.61 +3.11% $469.84M 73
PYNKF Perimeter Medical Imaging AI, Inc. $0.20 +3.40% $18.68M 73
SSII SS Innovations International, Inc. $3.76 -0.53% $752.49M 72
RSHUF Respiri Limited $0.06 +0.00% $91.52M 68
DNAY Codex DNA, Inc. $1.30 +8.33% $38.32M 68
SENS Senseonics Holdings, Inc. $5.66 +3.36% $236.74M 67
PROF Profound Medical Corp. $7.21 +5.87% $218.16M 67
DMTRF 3-D Matrix, Ltd. $2.50 +11.11% $300.53M 66

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VMD's Key Strengths?

  • Specialized focus on respiratory care.
  • Established direct-to-patient service model.
  • Strong relationships with healthcare providers.
  • Comprehensive respiratory disease management programs.

What Are VMD's Weaknesses?

  • Reliance on reimbursement rates from insurance and government programs.
  • Limited geographic presence compared to larger competitors.
  • Potential for regulatory changes impacting DME industry.
  • Relatively small market capitalization.

What Could Drive VMD Stock Higher?

  • Expansion into new geographic markets, increasing patient reach.
  • Development and launch of new respiratory care technologies.
  • Strategic partnerships with healthcare providers to integrate Viemed's solutions.
  • Increasing prevalence of COPD and sleep apnea driving demand for services.

What Are the Key Risks for VMD?

  • Changes in reimbursement policies impacting revenue.
  • Increased competition from larger DME providers.
  • Regulatory scrutiny and compliance requirements.
  • Economic downturn impacting healthcare spending.
  • Supply chain disruptions affecting equipment availability.

What Are the Growth Opportunities for VMD?

  • Growth opportunity 1: Expansion of Sleep Apnea Solutions: Viemed has the opportunity to significantly expand its presence in the sleep apnea market. The global sleep apnea devices market is projected to reach $5.2 billion by 2027. By leveraging its existing infrastructure and expertise in respiratory care, Viemed can offer comprehensive sleep apnea testing and treatment solutions, including PAP devices and related services. This expansion can drive revenue growth and diversify its revenue streams.
  • Growth opportunity 2: Geographic Expansion: Viemed can pursue geographic expansion by entering new markets within the United States. Currently, the company operates in select regions. By expanding its service network to underserved areas, Viemed can tap into new patient populations and increase its market share. This expansion can be achieved through strategic acquisitions or organic growth, with a focus on regions with high prevalence of COPD and sleep apnea.
  • Growth opportunity 3: Strategic Acquisitions: Viemed can pursue strategic acquisitions of smaller DME providers or respiratory care companies. These acquisitions can provide access to new technologies, expand its product portfolio, and increase its market presence. Synergies from these acquisitions can drive cost efficiencies and improve profitability. The company can target companies with complementary services or technologies to enhance its overall value proposition.
  • Growth opportunity 4: Technological Innovation: Viemed can invest in technological innovation to develop new and improved respiratory care solutions. This includes developing more advanced ventilators, PAP devices, and remote monitoring technologies. By staying at the forefront of technological advancements, Viemed can differentiate itself from competitors and attract new customers. This innovation can also lead to improved patient outcomes and reduced healthcare costs.
  • Growth opportunity 5: Partnerships with Healthcare Providers: Viemed can establish partnerships with hospitals, physician groups, and other healthcare providers to integrate its respiratory care solutions into their existing care pathways. These partnerships can provide access to a broader patient base and enhance its brand reputation. By collaborating with healthcare providers, Viemed can improve patient outcomes and reduce hospital readmission rates for patients with COPD and other respiratory conditions.

What Opportunities Does VMD Have?

  • Expansion into new geographic markets.
  • Growth in the sleep apnea market.
  • Strategic acquisitions of smaller DME providers.
  • Development of new respiratory care technologies.

What Threats Does VMD Face?

  • Increased competition from larger DME providers.
  • Changes in reimbursement policies.
  • Potential for product recalls or safety concerns.
  • Economic downturn impacting healthcare spending.

What Are VMD's Competitive Advantages?

  • Specialized expertise in respiratory care and DME.
  • Established relationships with healthcare providers and payers.
  • Proprietary respiratory disease management programs.
  • Direct-to-patient service model.

What Does VMD Do?

Viemed Healthcare, Inc., established in 2006 and headquartered in Lafayette, Louisiana, operates as a provider of in-home durable medical equipment (DME) and post-acute respiratory healthcare services across the United States. The company focuses on delivering comprehensive respiratory disease management solutions, primarily targeting patients with chronic obstructive pulmonary disease (COPD) and sleep apnea. Viemed’s core offerings include non-invasive ventilation, percussion vests, and other respiratory therapies, along with the provision of invasive and non-invasive ventilators and related equipment. Viemed leases a range of equipment, including ventilators, positive airway pressure (PAP) machines, oxygen concentrator units, and other respiratory devices. The company also sells and rents DME and offers patient medical services. Beyond respiratory care, Viemed provides neuromuscular care and oxygen therapy services, as well as sleep apnea management solutions, including PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Furthermore, Viemed offers in-home sleep apnea testing services, enhancing its comprehensive approach to respiratory healthcare. The company's direct-to-patient model and focus on chronic respiratory conditions differentiate it within the broader healthcare landscape.

What Products and Services Does VMD Offer?

  • Provides in-home durable medical equipment (DME).
  • Offers post-acute respiratory healthcare services.
  • Delivers respiratory disease management solutions for COPD.
  • Leases non-invasive and invasive ventilators.
  • Provides sleep apnea management solutions and equipment.
  • Offers in-home sleep apnea testing services.
  • Sells and rents DME and patient medical services.

How Does VMD Make Money?

  • Generates revenue through leasing and selling durable medical equipment.
  • Provides respiratory therapy and related services, reimbursed by insurance and government programs.
  • Offers in-home testing services for sleep apnea and other respiratory conditions.
  • Focuses on chronic respiratory disease management for recurring revenue.

What Industry Does VMD Operate In?

Viemed Healthcare operates within the medical devices industry, specifically focusing on respiratory care and durable medical equipment (DME). The industry is characterized by increasing demand for home healthcare solutions, driven by an aging population and the rising prevalence of chronic respiratory diseases like COPD and sleep apnea. The competitive landscape includes established DME providers and manufacturers of respiratory equipment. Viemed differentiates itself through its focus on in-home respiratory care and comprehensive disease management programs. The global medical devices market is projected to reach $600 billion by 2025, indicating substantial growth potential.

Who Are VMD's Key Customers?

  • Patients with chronic obstructive pulmonary disease (COPD).
  • Patients with sleep apnea.
  • Hospitals and healthcare providers.
  • Individuals requiring in-home respiratory care.
AI Confidence: 73% Updated: May 9, 2026

How Viemed Healthcare, Inc. Is Valued

Viemed Healthcare, Inc. carries a market capitalization of $472.12M, placing it in the small-cap category. Relative to its peer group, VMD's quantitative score of 91/100 is above the peer average of 71/100.

Company Profile

Viemed Healthcare, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Lafayette, US. The company is led by CEO Casey Hoyt. VMD has traded publicly since 2019.

ROE 11%Key Financial Metrics

Return on equity for Viemed Healthcare, Inc. stands at 10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.5%, showing how much profit it generates from its asset base. VMD trades at a trailing price-to-earnings ratio of 26.89, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Viemed Healthcare, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.01 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Viemed Healthcare, Inc. revenue of about $317.3M for fiscal 2026, with EPS near $0.46.

VMD Financials

Fundamental Snapshot

Revenue Growth (FY)
+20.5%
Net Income Growth (FY)
+32.6%
EPS Growth (FY)
+31.0%
P/E (TTM)
31.0
Return on Equity (TTM)
+10.7%
Current Ratio
1.2
EV/EBITDA (TTM)
8.7

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
  • Community sentiment has shifted positively, with discussions highlighting Viemed's innovative approach to healthcare solutions.
  • Analysts have noted an increasing demand for respiratory care services, positioning Viemed favorably in a growing market.
  • Recent partnerships and contracts have bolstered the company's reputation, enhancing its visibility and credibility in the healthcare sector.

Bear Case

  • Concerns about regulatory changes in the healthcare industry have created uncertainty around future operations and profitability.
  • Social sentiment has shown some skepticism regarding the sustainability of Viemed's growth, with some community members questioning its long-term strategy.
  • Competitive pressures in the healthcare market have intensified, raising concerns about Viemed's ability to maintain its market share.
  • Recent earnings reports have not met market expectations, leading to doubts about the company's operational efficiency and financial health.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

VMD Latest News

VMD Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VMD.

Price Targets

Consensus target: $13.00

VMD MoonshotScore

91/100

What does this score mean?

The MoonshotScore rates VMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Casey Hoyt

CEO

Casey Hoyt serves as the Chief Executive Officer of Viemed Healthcare, Inc. His background includes extensive experience in the healthcare industry, with a focus on durable medical equipment and respiratory care services. Prior to his role at Viemed, Hoyt held various leadership positions in healthcare organizations, where he focused on operational efficiency, strategic planning, and market expansion. His expertise spans across business development, sales management, and healthcare administration.

Track Record: Under Casey Hoyt's leadership, Viemed Healthcare has expanded its geographic reach and service offerings, particularly in the sleep apnea market. He has overseen the development and implementation of innovative respiratory disease management programs, contributing to improved patient outcomes and reduced healthcare costs. Hoyt has also focused on strategic acquisitions to enhance Viemed's market position and expand its product portfolio. He has successfully navigated regulatory challenges and reimbursement pressures within the healthcare sector.

What Investors Ask About Viemed Healthcare, Inc. (VMD) — Healthcare

What does Viemed Healthcare, Inc. do?

Viemed Healthcare, Inc. specializes in providing in-home respiratory care solutions and durable medical equipment (DME) to patients in the United States. The company focuses on managing chronic respiratory diseases such as COPD and sleep apnea by offering non-invasive ventilation, oxygen therapy, and sleep apnea testing services. Viemed's business model involves leasing and selling DME, as well as providing respiratory therapy and related services, primarily reimbursed by insurance and government programs. The company's direct-to-patient service model and comprehensive disease management programs differentiate it within the healthcare landscape.

What do analysts say about VMD stock?

Analyst coverage of Viemed Healthcare, Inc. (VMD) typically focuses on its growth potential within the respiratory care market and its ability to expand its geographic reach and service offerings. Key valuation metrics often include revenue growth, profit margins, and free cash flow. Analysts consider the company's ability to navigate regulatory challenges and reimbursement pressures within the healthcare sector. Consensus estimates may vary, but generally reflect expectations for continued growth driven by the increasing prevalence of COPD and sleep apnea. Investors should conduct their own due diligence and consider multiple sources of information.

What are the main risks for VMD?

Viemed Healthcare, Inc. faces several risks, including potential changes in reimbursement policies that could impact revenue. Increased competition from larger DME providers and regulatory scrutiny pose ongoing challenges. Economic downturns could affect healthcare spending, while supply chain disruptions could impact equipment availability. The company's reliance on insurance and government programs for reimbursement makes it vulnerable to policy changes. Investors should carefully consider these risks when evaluating Viemed Healthcare, Inc.

What are the key factors to evaluate for VMD?

Viemed Healthcare, Inc. (VMD) holds an AI score of 91/100 (high). P/E: 26.9x vs the S&P 500's ~20-25x. Analysts target $13.00 (+6%). Not financial advice.

How frequently does VMD data refresh on this page?

VMD prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven VMD's recent stock price performance?

Viemed Healthcare, Inc. (VMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on respiratory care. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider VMD overvalued or undervalued right now?

Viemed Healthcare, Inc. (VMD) trades at 26.9x earnings. Analysts target $13.00 (+6%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying VMD?

Before investing in Viemed Healthcare, Inc. (VMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks